Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Effectiveness and Safety of Odronextamab Compared to Standard Treatment in Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called B-cell non-Hodgkin's lymphoma, which is a cancer that affects the lymphatic system, part of the body's immune system. The study is evaluating a new treatment called odronextamab (also known by its code name REGN1979), which is a special type of medication known as a bispecific antibody. This means it is designed to target two different proteins at once, potentially helping the immune system to better fight the cancer. The trial aims to compare the effectiveness and safety of odronextamab against the standard treatments currently used for this type of cancer.

Participants in the study will receive either odronextamab or one of the standard treatments, which may include medications like cisplatin, gemcitabine, carboplatin, dexamethasone, cytarabine, rituximab, etoposide, or ifosfamide. These treatments are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The study will last for several months, during which participants will be closely monitored by healthcare professionals to assess how well the treatments are working and to check for any side effects.

The main goal of the study is to see how long participants can live without their cancer getting worse, which is known as event-free survival. Other aspects being studied include how long participants live overall, how their quality of life changes, and how their bodies respond to the treatments. This information will help researchers understand if odronextamab could be a better option for treating aggressive B-cell non-Hodgkin's lymphoma compared to the current standard treatments.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying the diagnosis of aggressive B-cell non-Hodgkin's lymphoma and ensuring the availability of tumor tissue for analysis.

    The assessment also checks for measurable disease through imaging tests and evaluates overall health status, including organ function and performance status.

  2. Step 2

    Treatment assignment

    Participants are randomly assigned to receive either odronextamab or standard of care treatment. The assignment is open-label, meaning both the participant and the healthcare provider know which treatment is being administered.

  3. Step 3

    Treatment phase

    For those receiving odronextamab, the medication is administered intravenously. The specific dosage and frequency are determined by the study protocol and the healthcare provider.

    Participants receiving standard of care may be treated with a combination of medications such as cisplatin, gemcitabine, carboplatin, dexamethasone, cytarabine, rituximab, etoposide, and ifosfamide. These are also administered intravenously, except for dexamethasone, which is taken orally.

  4. Step 4

    Monitoring and follow-up

    Throughout the treatment, regular monitoring is conducted to assess the effectiveness and safety of the therapy. This includes imaging tests to evaluate tumor response and blood tests to monitor health status.

    Participants are also monitored for any side effects or adverse reactions to the treatment.

  5. Step 5

    End of treatment evaluation

    At the end of the treatment phase, a comprehensive evaluation is performed to determine the overall response to the therapy. This includes assessing event-free survival and other outcomes as defined by the study protocol.

    Participants may continue to be monitored for long-term outcomes and any late-onset side effects.

Who can join the trial?

9 criteria

  • The patient must have a type of cancer called B-Cell Non-Hodgkin's Lymphoma, which is confirmed by a test called a histological test. This means a sample of the tumor is examined under a microscope.
  • The patient must have tumor tissue available for testing in a central laboratory. This can be a new sample or an older one that was taken before joining the study.
  • The patient must have cancer that either did not respond to the first treatment or came back within 12 months after starting the first treatment. The first treatment should have included a specific type of medicine called an anti-CD20 antibody and another type called an anthracycline.
  • The patient must have a tumor that can be measured. This means there is at least one lymph node with a size greater than 1.5 cm or another type of tumor with a size greater than 1.0 cm, as shown by a scan like a CT scan or MRI.
  • The patient should plan to have a procedure called an Autologous stem cell transfer, which is a treatment that uses the patient's own stem cells.
  • The patient must have an ECOG performance status of 0 to 1. This is a scale that measures how well a patient can perform daily activities, with 0 being fully active and 1 being restricted in physically strenuous activity but able to carry out light work.
  • The patient must have adequate blood and organ function, meaning their blood and organs are working well enough to participate in the study.
  • Other specific criteria defined in the study protocol may also apply.
  • The study is open to both male and female patients.

Who cannot join the trial?

5 criteria

  • Patients who have a different type of cancer other than B-Cell Non-Hodgkin's Lymphoma cannot participate. This is a specific type of cancer that affects certain white blood cells called B-cells.
  • Patients who are not within the specified age range for the study cannot participate. The study has specific age requirements.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, are not eligible for this study.
  • Patients who are not able to follow the study procedures or take the study medication as required cannot participate.
  • Patients who have any other medical conditions that might interfere with the study or make it unsafe for them to participate are not eligible.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Odronextamab (REGN1979)

    is a bispecific antibody designed to target two proteins, CD20 and CD3. It is used in this trial to treat patients with aggressive B-cell non-Hodgkin lymphoma that has either returned after treatment or has not responded to previous treatments. The medication works by helping the immune system recognize and attack the cancer cells more effectively.

  • Standard of Care Therapy

    refers to the usual treatment given for aggressive B-cell non-Hodgkin lymphoma. This can include a variety of chemotherapy drugs, targeted therapies, or other treatments that are commonly used and accepted by medical professionals to manage this type of cancer. The specific treatments used as standard care can vary depending on the patient's previous treatments and overall health.

What is already known about the treatment

Odronextamab – This medication is administered intravenously, meaning it is given directly into a vein. It is currently being studied in clinical trials for its effectiveness in treating B-cell Non-Hodgkin's Lymphoma, particularly in cases where the disease has returned or is resistant to standard treatments. Odronextamab is a bispecific antibody that targets both CD20 and CD3 proteins, helping the immune system to recognize and attack cancer cells. It falls under the pharmacological classification of monoclonal antibodies.

Investigated diseases

B-Cell Non-Hodgkin's Lymphoma – This is a type of cancer that originates in the lymphatic system, specifically affecting B-lymphocytes, which are a type of white blood cell. It is characterized by the uncontrolled growth of these cells, leading to the formation of tumors in lymph nodes and other parts of the body. The disease can vary significantly in its progression, with some forms being slow-growing and others more aggressive. Symptoms may include swollen lymph nodes, fever, night sweats, and weight loss. The progression of the disease can lead to the spread of cancerous cells to other organs and tissues. The exact cause of B-Cell Non-Hodgkin's Lymphoma is not well understood, but it involves genetic mutations in the B-cells.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-502783-21-00Protocol codeR1979-HM-2299Estimated enrolment256 patientsSponsorRegeneron Pharmaceuticals Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.